Characteristics and outcomes of angiovac-assisted debulking of intracardiac masses, thrombi, and endocarditis

Clin Res Cardiol. 2023 May;112(5):626-632. doi: 10.1007/s00392-022-02146-4. Epub 2022 Dec 30.

Abstract

Background: Traditional management for right-sided infective endocarditis and other adherent masses centers around balancing the risks and benefits of open surgical removal against medical therapy.

Methods: Single-center study analysis of 19 patients who underwent vacuum-assisted debulking and/or en bloc removal of right-sided infective endocarditis and other adherent masses between September 2017 and November 2021. Clinical outcomes during the perioperative period, postoperative period, hospital course, and post-discharge were analyzed.

Results: We included 12 male and 7 female patients with an average age 47.4 ± 16.8. Relevant risk factors included 47.4% of patients with active intravenous drug use (IVDU), 21.1% of patients with a history of permanent pacemaker (PPM) or implantable cardioverter-defibrillator (ICD), and 5.3% of prior malignancy with mediastinal radiation. 31.6% of patients had documented right-sided masses from a non-infectious etiology, while 68.4% of patients were noted to have right-sided infective endocarditis (RSIE). All patients were found to have large, mobile masses or vegetations at high risk for embolization to the pulmonary vasculature. Average in-hospital length of stay was 17.8 ± 12.2 days, blood cultures cleared postoperatively in 8.9 ± 7.3 days, periprocedural mortality was 0%, subsequent open surgical valvular repair during the same admission was 5.3%, and in-hospital mortality was 5.3%. Within 6 weeks of follow-up, 15.8% of patients were readmitted for recurrence of bacteremia, 10.5% of patients were found to have new pulmonary embolism, and 15.8% of patients underwent open surgical valvular repair. Total death after 1-year and 2-years was 15.8% and 5.3%, respectively. Recurrence of bacteremia was 21.1% within 1-year.

Conclusion: AngioVac is a viable therapeutic strategy for select patients with intravascular and intracardiac right-sided masses including thrombi, emboli, or infective masses such as endocarditis.

Keywords: AngioVac; Bypass; ECMO; Emboli; Endocarditis; Interventional Cardiology; Myxoma; Right-sided infective endocarditis; Thrombectomy; Thrombi.

MeSH terms

  • Adult
  • Aftercare
  • Cytoreduction Surgical Procedures
  • Endocarditis* / diagnosis
  • Endocarditis* / surgery
  • Endocarditis, Bacterial* / diagnosis
  • Endocarditis, Bacterial* / surgery
  • Female
  • Humans
  • Male
  • Middle Aged
  • Patient Discharge
  • Thrombosis* / therapy